Neutralization antigenic sites of equine arteritis virus (EAV) were examined with neutralization resistant (NR) mutants generated by two monoclonal antibodies (MAbs; 1A1 and 4G8
Equine arteritis virus (EAV) is the etiological agent of a febrile disease of horses [14] . EAV is a small enveloped virus with positive stranded polyadenylated RNA of about 12.7 Kb [6] . The virus-infected cells contain a 3'-coterminal nested set of six subgenomic mRNAs [6, 8] . As the genomic organization and replication strategies are similar to those of the coronavirus family, it was proposed to classify EAV as a corona-like superfamily or a new Arteriviridae along with lactate dehydrogenase elevating virus, simian hemorrhagic fever virus and porcine reproductive and respiratory syndrome virus [5, 6, 18, 19] . The genome contained 8 overlapping open reading frames (ORFs). De Vries et al. identified four structural proteins of EAV, consisting of glycosylated 25-kDa protein, glycosylated 30-to 42-kDa (G L ) protein, membrane protein and nucleocapsid protein encoded by ORF 2, 5, 6 and 7, respectively [9] . G L protein is supposed to be a major envelope protein.
Only one serotype of EAV has been recognized, but minor antigenic differences among EAV isolates were demonstrated by serological tests [11, 12] . And the antigenic variation among the isolates was identified by neutralizing monoclonal antibodies (MAbs) [13, 16] . Neutralizing MAbs recognizing a single site or overlapping sites on the G L protein have recently been identified, and the MAbs are predicted to recognize amino acid position between 99 and 113 [1, 2, 13] . Chirnside et al. generated EAV-neutralizing antibody by inoculation with a G L -specific synthetic peptide at different region from previous reports [4] . The G Lspecific synthetic peptide may contain one of the major neutralization antigenic sites. In this study, we identified new two neutralization antigenic sites, one of them located in the region of the synthetic peptide.
Materials and Methods
Viruses and Cells: RK-13 cells were used for all virus propagation. The cells were grown in MEM supplemented with 10% fetal calf serum, 0.1% NaHCO 3 and antibiotics and maintained at 37°C, 5% CO 2 in air.
Bucyrus (B) strain was used for MAb production [10] . Modified Bucyrus (MB) strain of EAV was plaquepurified and used for cloning of cDNA clones and for This article was submitted November 21, 1996, and was accepted February 5, 1997. *corresponding author. generation of neutralization resistant (NR) mutants [17] . We used MB strain for the generation of NR mutants, because we confirmed that the MB strain had the same antigenicity as the B strain to both of the MAbs used in this experiment and characterized by sequence analysis in our laboratory.
Neutralizing MAbs: Neutralizing MAbs were generated by immunizing Balb/c mice with sucrose gradient purified B strain of EAV as described previously [16] . Two ascitic MAbs, 1A1 and 4G8, used in this study had similar antigenicity to B and MB strains of EAV [16] .
Generation of NR mutants: MB strain of EAV with 10 6.5 PFU/ml was used as parental virus for generation of NR mutants. A ten-fold serial dilution of the MB strain was made in a 96-well microplate and mixed with an equal volume of 1A1 or 4G8 ascitic MAb, which contained more than 1,000-fold excess of neutralization antibody titer determined by 50% plaque reduction. Three rows of dilution were used for each MAb. After incubation for 1 hr at 37°C, RK-13 cells were added to each well and incubated for 6 days at 37°C. Three wells showing a cytopathic effect (CPE) were used for plaque purification of the virus three times in each MAb. Among CPE-positive wells, the highest virus dilution in each row were selected. The stab-neutralization method (SNM) was applied to analyze neutralization resistance [15] . Briefly, the RK-13 monolayer cells were overlayed with agar medium containing each MAb or without MAb as a control. The final neutralization titer of MAbs in agar medium was adjusted to 1:100. The plaque purified mutants and parental virus were inoculated from the top of the agar by stubbing with a virus-attached toothpick. Virus samples used in this method were harvested when CPE became maximum in RK-13 culture. Monolayers were fixed and stained with staining solution containing 5% formalin and 0.1% crystal violet in PBS after 4 days inoculation. Neutralization resistance was judged by the diameter of the CPE area on the monolayer (Fig. 1 ).
Immunofluorescence test (IFT):
Indirect IFT was applied to determine the binding activity of the MAbs to the mutants and the parental virus. Virus-infected RK-13 cells were fixed with acetone and used to examine the binding activity of MAbs to intra-cellular antigen. To examine the binding activity to surface antigen in live cells, virus-infected cells were scrapped from the culture plate, washed with PBS, then react with MAb and antimouse IgG-FITC conjugate at 4°C for 1 hr each.
cDNA cloning of viral RNA: Viral RNA was extracted from virus inoculated culture medium by the SDS-phenol method. Briefly, 3 ml of viral samples were treated with 1% SDS and extracted with phenol-chloroform. The extracted RNA was recovered by precipitation in ethanol. cDNA was synthesized with murine leukemia virus reverse transcriptase (GIBCO-BRL) and random 9-mer primer. Double-stranded cDNAs covering the structural protein-coding region were synthesized by means of PCR with Taq polymerase and four pairs of oligonucleotide primers. The sequence of the primers used was 1a (5'GCACTAGAGGGATGTAAACC3'), 1b (5'AGT-GCACTAACATAGTGACC3'), 2a (5'ATGTCAC-CTTCCCGTCGCAC3'), 2b (5'AAATTGGCAAT-AACGCCGCG3'), 3a (5'GTTTTATGTTCTTTTA-CGACTGG3'), 3b (5'ATACTCACCTAAAATCCCG-TC3'), 4a (5'TACGGCAGCAAAGTCAACCT3') and 4b (5'TGGTTCCTGGGTGGCTAATA3'). The PCR products were cloned into pCRII vector plasmid (Invitrogen). More than two clones were used for DNA sequencing.
Sequence analysis: To identify amino acid substitution of NR mutants, the nucleotide sequence of the viral protein-coding region, from ORF2 to ORF7, was determined by the dideoxynucleotide chain termination method with a cycle sequencing kit (Pharmacia Biotech). Sequences were obtained from more than two cDNA clones and both cDNA strands in the same region in order to eliminate reading errors introduced by Taq polymerase. Nucleotide and amino acid sequence data were assembled and analyzed with GENETYX computer software (Software Development).
Results
Neutralization resistance of the mutants: Three cloned EAVs were obtained from each MAb treated sample. They were examined for neutralization resistance by SNM. CPE sizes of two viruses generated from 1A1 (1A1-R1 and -R2) (Fig. 1b) were similar to the CPE in the control plate (Fig. 1a) . The result indicates that these two viruses are resistant to 1A1. On the other hand, three viruses generated from 4G8 (4G8-R1, -R2 and -R3) were resistant to 4G8 (Fig. 1a and c) . Therefore, these five viruses were determined to be NR mutants by SNM and used for further analysis. 1A1-R3 was not an NR mutant. The NR mutants were resistant only to the MAb used for generation but not resistant to the other MAb (Table 1 and Fig. 1 ). These results indicated that 1A1 and 4G8 recognized two distinct neutralization antigenic sites.
Binding activity of MAbs to the mutants: Both MAbs bound to intra-cellular antigen in fixed cells and surface antigen on live cells infected with parental virus but the MAbs lose binding activity to neither antigen of the NR mutants-infected cells. Binding activity of MAbs was lost only to the NR mutants generated by the same MAb ( Table 1) .
Location of amino acid substitutions in the NR mutants: Five mutants were used for sequence analysis in 1A1 and 4G8 NR mutants, respectively. From the results of sequencing of the viral protein-coding region (data not shown), the presence of deduced amino acid substitution could be detected only in G L protein. All the NR mutants had substitution in one amino acid except 4G8-R2 (two substitutions at positions 84 and 167). 1A1-derived mutants had mutation at position 60 (Ser to Arg) or 61 (Lys to Glu) and 4G8-derived mutants had mutation at position 84 (Thr to His) ( Fig. 2) . These results revealed that EAV had at least two distinct neutralization antigenic sites which include amino acid of the 60th to 61st and 84th residues of G L protein.
The amino acid substitutions of the five NR mutants were located in or close to hydrophilic regions of deduced amino acid sequence (Fig. 3) . The substitutions of amino acid occurred between different properties of amino acid, such as uncharged to positively charged R group (Ser to Arg and Thr to His) and positively to negatively charged R group (Lys to Glu). These substitutions caused a strong change in charge and hydrophilicity around the substituted positions.
Discussion
In this report, we found that the two MAbs recognized two distinct neutralization antigenic sites using a SNM [15] , which is a practical method to examine the neutralization sensitivity of many virus strains. Analysis of neutralization resistance has been performed by neutralization test or plaque reduction test with serial dilution of antisera. The SNM has the advantage of using less precious antisera or MAbs. Moreover it is not necessary to adjust the infectivity of the mutant virus for this neutralization test. This method therefore offers a great advantage by saving cost and time.
We generated more than two NR mutants for each MAb from independent wells. Analyzing plural mutants makes the result more accurate. Especially in the mutation analysis, we can reveal the distribution of MAb-binding site with plural NR mutants. As NR mutants generated by MAbs became resistant only to a homologous MAb and not resistant to a heterologous MAb, the two MAbs recognize different antigenic sites from each other.
IFT was applied to examine the binding activity of the MAbs, because both sequential and conformational epitopes can be examined by this test. The results of IFT indicated that amino acids in the neutralization epitope in NR mutants changed and the epitope loses reactivity to bind with the MAb. The neutralizing MAbs used in this study recognized antigen expressed on the cell membrane of the virus-infected cells, such as the In sequence analysis of NR mutants, significant mutations of deduced amino acids (at positions 60-61 and 84) were identified only in G L protein. Amino acid mutation at position 167 in 4G8-R2 may not contribute to neutralization resistance, because this virus has a mutation at position 84 as do other mutants. MAb 1A1 and 4G8 recognized a neutralization epitope including positions 60 to 61 and 84 in G L protein , respectively. All three NR mutants generated by 4G8 possessed mutation at position 84, and this amino acid therefore seemed the most critical position for the 4G8 neutralization epitope.
The results indicated in this report confirmed previous reports in terms of neutralization antigen protein, G L protein [1, 2, 4, 7, 13] [1, 13] . Our results and these indicated that there may be several neutralization antigenic sites on the EAV virion. Chirnside et al. has generated neutralizing antibody in horse by immunization with a G L -specific synthetic peptide (positions 75 through 97) [4] . As they failed to generate a neutralizing antibody with expressed proteins of other regions in G L , the region of the synthetic peptide may contain a major neutralization antigenic site. The neutralization antigenic site recognized by 4G8 is located just inside the peptide. This site may therefore be the major neutralization antigenic site of the EAV.
The neutralization sites identified in this study are located in or very close to the V 1 variable region (position from 61 to 121) described by Balasuriya et al. [3] . Critical amino acids for neutralization identified in this study are located in the hydrophilic domain and therefore the amino acids seems to be exposed to the surface of the neutralization epitope of the G L protein (Fig. 3) . The MAbs lost binding activity with NR mutants, because substitutions of amino acids occurred between different properties of amino acids, and the conformation and charge of epitopes may change considerably. The defined antigenic sites of G L are likely to contain the major neutralizing antigenic site and consequently may be useful in the development of component or recombinant vaccines.
